Long-term Octreotide Therapy

Side Effects and Complications

• Steatorrhea is a common but generally mild side effect of octreotide therapy, potentially impacting patient quality of life, with weight gain of approximately 1% despite mild steatorrhea 1
• Pulse rate is suppressed during treatment, which may be a consideration for patients with pre-existing heart conditions 1
• Sustained symptom control is achieved in most patients, with long-term studies showing minimal serious complications, although discontinuation rate is up to 47% due to side effects or lack of efficacy 1
• Quality of life is significantly improved with long-acting formulations, which are generally preferred by patients due to less frequent administration, allowing most patients to resume employment during long-term treatment 1

Treatment Outcomes and Management

• Long-acting formulations are associated with significant improvements in quality of life, making them a preferred option for many patients, while short-acting formulations may be more effective for certain conditions like hypoglycemia, but require more frequent injections 1
• Octreotide affects the gastrointestinal tract by decreasing gastric, biliary, and pancreatic secretions, inhibiting secretagogue-induced water and electrolyte secretion, and inhibiting the release of hormones that contribute to diarrhea, which can impact enteral feeding in patients with jejunal tube feeds 2
• The American Gastroenterological Association and the European Society for Clinical Nutrition and Metabolism recommend using continuous infusion rather than bolus feeding for patients on octreotide to prevent dumping and manage diarrhea better in patients with jejunal tube feeds 3
• Daily monitoring of stoma output volume, weight, urine output, and serum electrolytes is recommended for patients on jejunal tube feeds and octreotide, along with assessment for signs of dehydration and potential fluid retention, and evaluation of nutrient absorption to adjust feeding rates accordingly 4
• Feeds should be chosen based on the patient's nutritional requirements, considering any abnormalities of gastrointestinal absorption or motility, and adjusting for any system abnormalities (renal or liver failure) in patients with jejunal tube feeds on octreotide, as recommended by the American Society for Parenteral and Enteral Nutrition 3
• Octreotide should be administered before meals (or feeding increases) as intestinal output typically rises after eating in patients on jejunal tube feeds, with an initial dose of subcutaneous octreotide typically 50 mcg twice daily, according to the Clinical Nutrition guidelines 4
• Octreotide may reduce fat absorption in some patients with jejunal tube feeds and can effectively reduce ileostomy diarrhea and large-volume jejunostomy output in patients with short bowel syndrome, allowing for a daily reduction in intravenous fluid requirements 2
• Regular assessment of feed tolerance is essential to minimize potential side effects and interactions, and careful monitoring is necessary to prevent significant fluid retention when initiating octreotide treatment 2